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Abstract: Pancreatic cancer has a poor prognosis, in part due to lack of early detection. The identiﬁ  cation of circulating 
tumor antigens or their related autoantibodies provides a means for early cancer diagnosis. We have used a proteomic ap-
proach to identify proteins that commonly induce a humoral response in pancreatic cancer. Proteins from a pancreatic ad-
enocarcinoma cell line (Panc-1) were subjected to two-dimensional PAGE, followed by Western blot analysis in which 
individual sera were tested for autoantibodies. Sera from 36 newly diagnosed patients with pancreatic cancer, 18 patients 
with chronic pancreatitis and 15 healthy subjects were analyzed. Autoantibodies were detected against a protein identiﬁ  ed 
by mass spectrometry as vimentin, in sera from 16/36 patients with pancreatic cancer (44.4%). Only one of 18 chronic 
pancreatitis patients and none of the healthy controls exhibited reactivity against this vimentin isoform. Interestingly, none 
of several other isoforms of vimentin detectable in 2-D gels exhibited reactivity with patient sera. Vimentin protein expres-
sion levels were investigated by comparing the integrated intensity of spots visualized in 2-D PAGE gels of various cancers. 
Pancreatic tumor tissues showed greater than a 3-fold higher expression of total vimentin protein than did the lung, colon, 
and ovarian tumors that were analyzed. The speciﬁ  c antigenic isoform was found at 5–10 fold higher levels. The detection 
of autoantibodies to this speciﬁ  c isoform of vimentin may have utility for the early diagnosis of pancreatic cancer.
Introduction
There is substantial evidence for a humoral immune response to cancer in humans, demonstrated by the 
identiﬁ  cation of autoantibodies to a number of intracellular and surface antigens in serum from patients 
with different tumor types (1–3). A tumor-speciﬁ  c humoral immune response directed against oncopro-
teins (4–5), or mutated proteins such as p53 (6) or other aberrantly expressed proteins have been previ-
ously described. It is currently largely unknown whether the occurrence of such antibodies is beneﬁ  cial. 
However, knowledge of potential tumor antigens that may evoke tumor-speciﬁ  c immune responses may 
have relevance to the development of effective strategies for cancer screening and diagnosis.
Pancreatic cancer has the worst prognosis among cancers, with a 5-year survival rate of <3%, 
accounting for the fourth largest number of cancer deaths in the United States (7). The poor prognosis 
for pancreatic cancer is, in part, due to lack of early detection methods. Currently, there is a paucity of 
pancreatic cancer markers for early detection and for the diagnosis of pancreatic cancer. 
Autoimmunity in pancreatic cancer has been demonstrated against several proteins, including MUC1 
(8–9), p53 (9), calreticulin (13) and Rad51 (10) proteins. MUC1 is a transmembrane glycoprotein 
involved in cell-cell and cell-extracellular matrix interactions, and MUC1 autoantibodies have been 
observed in sera from patients with a variety of different tumors (11). The presence of MUC1 IgG 
autoantibodies has been shown to be associated with a favorable prognosis (8–9). The recombination 
factor Rad51 is highly expressed in pancreatic adenocarcinoma (10), and Rad51 autoantibodies have 
been observed in 7% of patients with pancreatic cancer.
A large number of autoantibodies have been identiﬁ  ed in various tumor types, but in most cases they 
occur in a small percentage of patient’s sera. Therefore, they are not effective individually for the early 
detection of cancer. Thus, the development of panels of such autoantibodies directed against a variety 
of tumor antigens may be effective (12).
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We have implemented a proteomic approach 
for the identiﬁ  cation of tumor antigens that elicit 
a humoral response in pancreatic cancer (13). In 
this study we have utilized the pancreatic cancer 
cell line Panc-1 as the source of tumor cell proteins 
for antigen identiﬁ  cation. We have utilized 2-D 
PAGE to separate protein constituents, followed 
by their transfer onto PVDF membranes. Sera from 
cancer patients and from controls were screened 
individually by Western blot analysis for antibodies 
that reacted against the resolved proteins. Mass 
spectrometric analysis was used for protein iden-
tiﬁ  cation. Within, we report the identiﬁ  cation of a 
vimentin isoform as an antigen that elicits a 
humoral immune response in pancreatic cancer.
Materials and Methods
Materials
All cell culture reagents, including Dulbecco’s 
modiﬁ  ed Eagle’s medium (DMEM, containing 
L-glutamine, sodium pyruvate and pyridoxine 
hydrochloride), Dulbecco’s phosphate buffered 
saline (PBS), fetal calf serum and penicillin/strep-
tomycin were obtained from Invitrogen (Carlsbad, 
CA). The mouse monoclonal anti-vimentin anti-
body (Clone V9) was purchased from Lab Vision 
Corp. (Fremont, CA). The horseradish peroxidase-
conjugated sheep anti-human IgG and the ECL 
(Enhanced Chemiluminescence) kits were 
obtained from Amersham (Piscataway, NJ). The 
Immobilon-P PVDF (polyvinylidene ﬂ  uoride) 
membranes were purchased from Millipore Corp. 
(Bedford, MA). The acrylamide used in the ﬁ  rst 
dimension electrophoresis, urea, ammonium 
persulfate and PDA (piperazine diacrylamide) 
were all purchased from BioRad (Rockville 
Center, NY). The acrylamide used in the second 
dimension electrophoresis was purchased from 
Serva (Crescent Chemical, Hauppauge, NY) and 
the carrier ampholytes (pH 4 to 8) and NP-40 were 
both purchased from Gallard/Schlessinger (Carle 
Place, NY). All other reagents and chemicals were 
obtained from either Fisher or Sigma and were of 
the highest purity available.
Sera, tumor tissues and cell lines
Serum and tumor tissue was obtained at the time 
of diagnosis following informed consent using 
IRB-approved guidelines. A total of 36 serum 
samples were obtained from patients with a 
conﬁ  rmed diagnosis of pancreatic adenocarcinoma 
who were seen in the Multidisciplinary Pancreatic 
Tumor Clinic at the University of Michigan 
Comprehensive Cancer Center.  Sera from the 
pancreatic cancer patients were randomly selected 
from a clinic population that sees, on average, at 
the time of initial diagnosis, 15% of pancreatic 
adenocarcinoma patients presenting with early 
stage (i.e. stage 1/2) disease and 85% presenting 
with advanced stage (i.e. stage 3/4). Inclusion 
criteria for the study included patients with a 
conﬁ  rmed diagnosis of pancreatic cancer, the 
ability to provide written, informed consent, and 
the ability to provide 40 ml of blood. Exclusion 
criteria included inability to provide informed 
consent, patients actively undergoing chemo-
therapy or radiation therapy for pancreatic cancer, 
and patients with other malignancies diagnosed 
or treated within the last 5 years. Sera were also 
obtained from 18 patients with chronic pancreatitis 
who were seen in the Gastroenterology Clinic at 
University of Michigan Medical Center and at the 
Catholic University of Daegu, in Daegu, South 
Korea, and from 15 control healthy individuals 
collected at University of Michigan under the 
auspices of the Early Detection Research Network 
(EDRN). The mean age of the tumor group was 
65.4 years (range 54–74 years) and from the 
chronic pancreatitis group was 54 years (range 
45–65). The sera from the normal subject group 
was age and sex-matched to the tumor group. All 
of the chronic pancreatitis sera were collected in 
an elective setting in the clinic in the absence of 
an acute ﬂ  are. All sera were processed using iden-
tical procedures. The samples were permitted to 
sit at room temperature for a minimum of 30 
minutes (and a maximum of 60 minutes) to allow 
the clot to form in the red top tubes, and then 
centrifuged at 1,300 × g at 4
oC for 20 minutes. 
The serum was removed, transferred to a polypro-
pylene, capped tube in 1 ml aliquots, and frozen. 
The frozen samples were stored at –70
oC until 
assayed. All serum samples were labeled with a 
unique identiﬁ  er to protect the conﬁ  dentiality of 
the patient. None of the samples were thawed more 
than twice before analysis. The human cancer cell 
lines used in this study were all individually 
cultured in Dulbecco’s modiﬁ  ed Eagle medium 
supplemented with 10% fetal bovine serum, 
100 units/ml penicillin and 100 units/ml strepto-
mycin (Invitrogen, Carlsbad, CA). 
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2-D PAGE and Western blot analysis 
After excision, the tumor tissue was immediately 
frozen at –80
oC. An aliquot was lysed in solubili-
zation buffer (8 M urea (Bio-Rad), 2% Nonidet 
P-40, 2% carrier ampholytes, pH 4–8 (Gallard/
Schlessinger), 2% β-mercaptoethanol, and 10 mM 
PMSF), then stored at –80
oC until use. Cultured 
Panc-1 pancreatic adenocarcinoma cells were 
harvested in 300 µl of solubilization buffer by using 
a cell scraper and stored at –80
oC until use. Proteins 
derived from the extracts of either cultured cells or 
solid tumors were separated into two dimensions 
as described previously (14). Brieﬂ  y, solubilized 
proteins were applied onto isoelectric focusing gels. 
Isoelectric focusing was performed using pH 4 to 
8 carrier ampholytes at 700 V for 16 h, followed 
by 1000V for an additional 2 h. The ﬁ  rst-dimension 
gel was loaded onto the second-dimension gel, after 
equilibration in 125 mM Tris, pH 6.8, 10% glycerol, 
2% SDS, 1% dithiothreitol, and bromophenol blue. 
For the second-dimension separation, a gradient of 
11 to 14 % acrylamide (Crescent Chemical) was 
used. Proteins were transferred to an Immobilon-P 
PVDF membrane (Millipore) or visualized by silver 
staining of the gels.
Western blotting
After transfer, membranes were incubated with a 
blocking buffer consisting of 10 mM Tris-HCl 
(pH 7.5), 50 mM NaCl, 1.8% nonfat dry milk, and 
0.01% Tween 20 for 2 h. The membranes were 
incubated for 1 h at room temperature with serum 
obtained from either patients or healthy individuals 
as a source of primary antibody at a 1:100 dilution. 
Following three washes with washing buffer (Tris-
buffered saline containing 0.01% Tween 20), the 
membranes were incubated with horseradish 
peroxidase-conjugated anti-human (Amersham) 
IgG antibodies at a dilution of 1:1000 for 1 h at 
room temperature. Immunodetection was accom-
plished by ECL (Enhanced Chemiluminescence 
(Amersham)) followed by autoradiography on 
Hyperﬁ  lm MP (Amersham). 
Vimentin detection by 
western blotting 
A mouse anti-vimentin (Clone V9) monoclonal anti-
body (Lab Vision Corporation, Fremont, CA) was 
used at 1:100 dilution for western blotting and was 
processed as for incubations with patient sera, with 
a horseradish peroxidase-conjugated anti-mouse IgG 
(Amersham) as the secondary antibody.
In-gel enzyme digestion 
and mass spectrometry 
For protein identiﬁ  cation by mass spectrometry, 
2-D gels were stained by a modiﬁ  ed silver staining 
method, and excised proteins were destained for 5 
min in 15mM potassium ferricyanide and 50 mM 
sodium thiosulfate as described (15). Following 
three washes with water, the gel pieces were dehy-
drated in 100% acetonitrile for 5 min, and then dried. 
Digestion was performed by addition of 100 ng of 
trypsin (Promega, Madison, WI) in 200 nM ammo-
nium bicarbonate. Following enzymatic digestion 
overnight at 37
oC, the peptides were extracted twice 
with 50 µl of 60% acetonitrile/1% triﬂ  uoroacetic 
acid. Following removal of acetonitrile by centrifu-
gation in a vacuum centrifuge, the peptides were 
concentrated by using pipette tips C18 (Millipore) 
and identiﬁ  ed by nanoﬂ  ow capillary liquid chroma-
tography coupled with electrospray quadrupole-time 
of ﬂ  ight tandem mass spectrometry (ESI Q-TOF 
MS/MS) in the Q-TOF micro (MicroMass, 
Manchester, U.K.). The acquired spectra were 
processed and searched against a non-redundant 
Swiss-Prot protein sequence database using protein-
Lynx Global Server (www.micromass.co.uk).
Results
Autoantibodies to pancreatic tumor 
proteins in sera from patients with 
pancreatic cancer
Panc-1 pancreatic tumor cell line proteins were 
resolved by 2-D PAGE, then transferred onto 
Immobilon-P PVDF membranes. Sera obtained 
from 36 newly diagnosed patients with pancreatic 
cancer, from 18 patients with chronic pancreatitis 
and from 15 healthy donors were screened indi-
vidually for the presence of antibodies to Panc-1 
pancreatic tumor cell line proteins (Table 1). Each 
membrane was treated with one serum sample as 
the primary antibody and with sheep anti-human 
IgG as the secondary antibody. In general, most 
pancreatic patient sera reacted against multiple 
proteins (Fig. 1). Some of the reactive proteins also 
reacted with control sera and thus were considered 
to represent nonspeciﬁ  c reactivity. The reactive 
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proteins most commonly observed with pancreatic 
cancer patient sera, but not with controls included 
one protein with an estimated molecular mass of 
55 kDa and a pI of 5. This protein showed reactivity 
with sera from 16 of 36 patients with pancreatic 
cancer (44.4%), with 1/18 sera (5.6%, p = 0.003 
(one-sided Fisher’s exact test)) from chronic 
pancreatitis patients and none of 15 (0%, p = 0.001 
(one-sided Fisher’s exact test)) sera from healthy 
donors (Table 1). Combining the chronic pancre-
atitis and healthy controls into a single group gave 
p = 4 × 10 – 5 (one-sided Fisher’s exact test) in 
comparison to cancer.
Identiﬁ  cation of the reactive protein 
as vimentin
The protein spot of interest was extracted from the 
gels following 2-D PAGE and silver staining, 
digested with trypsin and the resulting peptides 
were analyzed by ESI Q-TOF Tandem MS spec-
trometry. The acquired spectra were processed and 
searched against a non-redundant SwissProt protein 
sequence database using proteinLynx Global Server 
(www.micromass.co.uk). The sequence of 12 
tryptic peptides matched the predicted sequence of 
vimentin (MW 53.5 kDa. pI 5.1) (Fig. 2). The 
identity of this protein was conﬁ  rmed with 2-D 
Western blotting using Panc-1 whole-cell extracts 
and anti-vimentin mouse monoclonal antibody 
(Fig. 3). Interestingly, although a number of 
vimentin isoforms were detected by monoclonal 
anti-vimentin antibody from Panc-1 whole cell 
lysates, only one vimentin isoform showed reac-
tivity speciﬁ  cally with pancreatic cancer patient 
sera. We hypothesized that perhaps speciﬁ  c protease 
cleavage of intact vimentin resulted in the observed 
antigenicity. To this end, each of the three lowest 
vimentin isoforms which were reactive with 
patients serum (Fig. 3) were excised from modiﬁ  ed 
silver-stained gels (the uppermost isoform was not 
visualized in the silver-stained gels), then subjected 
to analysis by tandem mass spectrometry in order 
to search for vimentin-speciﬁ  c tryptic peptides. We 
found multiple peptide coverage (7–13 peptides for 
each isoform), spanning residues 78–400 for each 
 
Serum  Number of  Vimentin-positive  P value*
   subjects
Pancreatic cancer  36  16 (44.4%) 
Chronic pancreatitis  18  1 (5.6%)  P = 0.003
Healthy Individuals  15  0 (0%)  P = 0.001
Figure 1. (A) A silver-stained image of the Panc-1 pancreatic tumor cell line, (B) as compared with a Western blot of the Panc-1 cell line with 
serum from a patient with pancreatic cancer, and (C) normal serum. 
Table 1. Identiﬁ  cation of vimentin autoantibodies in patient’s sera.  P value is in comparison to pancreatic 
cancer *, one-sided Fisher’s exact test.
(A) (B) (C)
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of the three isoforms (data not shown). Thus, as the 
same peptide coverage was identiﬁ  ed for each of 
the isoforms, we were unable to ﬁ  nd evidence of 
protease cleavage leading to antigenicity of the 
speciﬁ  c vimentin isoform that was speciﬁ  cally 
reactive with pancreatic cancer patient’s serum. 
Moreover, although some peptide modiﬁ  cations 
were found, such as deamination, methylation, 
phosphorylation and hydroxylation, none were 
speciﬁ  c to the vimentin isoform that showed reac-
tivity speciﬁ  cally with pancreatic cancer patient’s 
serum (data not shown).
Role of glycosylation in 
vimentin antigenicity
We sought to determine whether aberrant vimentin 
glycosylation contributed to immunogenicity. 
Solubilized proteins from the Panc-1 cell line were 
subjected to N-deglycosylation by a combination 
Figure 3. Western blot analysis of vimentin with (A) sera from a pancreatic cancer patient, (B) from healthy individual, 
and (C) a monoclonal anti-vimentin antibody.  
Figure 2. Tandem mass spectrometry identiﬁ  cation of vimentin. The MS/MS spectrum of vimentin (obtained after trypsin digestion) is shown 
by analysis with ESI-Q-TOF, coupled with nanoﬂ  ow capillary high-performance liquid chromatography. The precursor ion shown in the ﬁ  gure 
is m/z 648.3487, and resultant peaks were searched against the non-redundant SwissProt protein sequence database using the ProteinLynx 
global server. A total of twelve tryptic peptides, as shown, matched the vimentin protein.  
(A) (B) (C)
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of Endoglycosidase F, Endo-α-N-acetylgalactosa-
minidase, and α-2–3, 6, 8, 9-Neuraminidase. The 
resulting products were separated by SDS electro-
phoresis and analyzed by Western blotting. 
Although the deglycosylated positive control 
revealed a demonstrable mobility shift by SDS-
PAGE, the deglycosylating enzyme treatment did 
not result in any mobility shifts of vimentin. Thus, 
Endoglycosidase F- sensitive glycosylation does 
not appear to be playing a role in the observed 
immunogenicity of the vimentin isoform (data not 
shown). 
Analysis of vimentin expression 
by 2-D PAGE 
We hypothesized that there might be changes in 
the expression level of the single minor antigenic 
isoform of vimentin that could lead to antigenicity 
in pancreatic cancer. Using 2-D PAGE, we exam-
ined the expression of the different vimentin 
isoforms in a variety of tissues and tumor types. 
The major vimentin isoforms were present in the 
different cell lines examined, including 6 pancre-
atic tumor cell lines, 4 lung tumor cell lines, 9 colon 
tumor cell lines and 33 ovarian tumor cell lines, at 
similar expression levels. A similar pattern of 
expression was also observed in 6 pancreatic 
tumors, 38 lung tumors, 7 colon tumors and 25 
ovarian tumors (Fig. 4), suggesting that the major 
vimentin isoforms were ubiquitously expressed. 
However, the minor isoform that was found to be 
antigenic was speciﬁ  c to just a subset of the tumor 
cell lines. We analyzed (by Western blot) different 
tumor cell lines for the speciﬁ  c isoform of vimentin 
that was immunogenic in pancreatic tumor patients. 
These cell lines were derived from 4 lung tumors 
(3 adenocarcinoma and 1 small cell), 2 pancreatic 
tumors, 2 breast tumors, 7 colon tumors, 1 neuro-
blastoma and 1 testes. Interestingly, the isoform of 
vimentin was only found in 4 of the cell lines 
analyzed (in the Panc-1 pancreatic, in the H23 and 
A549 lung adenocarcinoma, and in the Hs1 testes 
tumor cell lines), thus suggesting that expression 
of the antigenic isoform was cell line-speciﬁ  c. 
Additionally, we explored whether the antigenic 
isoform was overexpressed in a variety of different 
adenocarcinomas, including 18 colon, 16 ovarian, 
14 lung, 10 esophageal and pancreatic (4 tumor 
and 4 normal tissue). The integrated intensity 
Figure 4. Vimentin protein levels measured in human tumors and tumor cell lines. 2-D gels were prepared using solubilized proteins from 
a variety of human tumors and tumor cell lines, as described in “Materials and Methods”. Background corrected integrated intensity (volume) 
was measured (Visage software, Genomic Solutions, Ann Arbor, MI) for total vimentin. Bars represents the average intensities for 38 lung 
tumors, 6 pancreatic tumors, 7 colon tumors, 25 ovarian tumors, 4 lung cell lines, 6 pancreatic cell lines, 9 colon cell lines and 33 ovarian 
cell lines. 
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measurement of the antigenic isoform in each 
tumor type was directly compared to that of a 
neighboring non-antigenic vimentin isoform that 
is ubiquitously expressed in all tumor types exam-
ined. Interestingly, the antigenic isoform of 
vimentin was expressed at 5–10 fold higher levels 
relative to the ubiquitous isoform in pancreatic 
tumors compared to other tumor types, and was 
expressed at approximately 50% higher levels than 
that found in normal pancreas (Table 2). 
Discussion
We have implemented a proteomics-based 
approach to identify proteins that elicit a humoral 
response in pancreatic cancer patients. This 
approach allows screening by Western blot analysis 
of patient sera for antibodies that react against 
separated tumor cell proteins. This study was 
focused on a search for autoantibodies to pancreatic 
tumor proteins present in the Panc-1 cancer cell 
line. We have shown that a humoral response 
directed against a single isoform of vimentin 
occurred in 44.4% patients with pancreatic cancer. 
One out of 18 (5.6%) chronic pancreatitis patients 
and none of the noncancer controls exhibited reac-
tivity against the antigenic vimentin isoform. 
Intermediate ﬁ  laments are one of the three major 
cytoskeleton networks in higher eukaryotic cells. 
These ﬁ  laments consist of a number of different 
members, including vimentin and the cytokeratin 
proteins. Different types of intermediate ﬁ  lament 
protein genes are expressed depending on the tissue 
type. Little is known about the function of inter-
mediate ﬁ  laments in normal cells, although it is 
believed that they provide cellular integrity and 
resistance against mechanical stresses (16). Their 
tissue-speciﬁ  c expression in normal cells and differ-
ential expression/assembly in cancer is of great 
pathologic value in tumor diagnostics. Expression 
of vimentin has been postulated to play a role in 
invasiveness and metastasis in cervical carcinoma 
(17). However, Heatley et al. have shown that 
vimentin expression could not differentiate between 
benign and invasive breast lesions, although its 
expression was correlated with tumor grade and 
decreased survival in ductal carcinoma (18). 
To date, autoantibodies to different classes of 
intermediate ﬁ  laments, including vimentin, have 
been detected in human sera (19–22). Although the 
mechanism of induction of autoantibodies against 
vimentin still remains obscure, proteolysis of the 
intact, native protein may play a role in develop-
ment of autoimmunity. In a previous study we have 
demonstrated that a particular form of calreticulin 
elicits a humoral response in hepatocellular carci-
noma (23), with the reactive epitope occurring in 
a truncated form (CRT32, which includes the 
C-terminal portion), whereas the intact protein did 
not elicit reactivity. Importantly, in vitro studies 
have demonstrated that vimentin is subject to 
caspase-mediated proteolysis in an apoptosis-
related manner (24). Prasad et al. (25) have reported 
apoptosis-associated proteolysis of vimentin in 
human prostate epithelial tumor cells and demon-
strated that vimentin undergoes limited proteolysis 
in the apoptotic cells. Additionally, intact vimentin 
and some of its proteolytic fragments correspond 
to ubiquitinated polypeptides that are speciﬁ  c to 
the apoptotic process (26–27). Alcover et al. (27) 
have demonstrated that anti-vimentin antibodies 
in patients with autoimmune diseases interact 
 
Tumor   Gels  Spot A  Spot B  B/A
  Type Analyzed  measurement  measurement
Colon 18  0.668  ± 0.255 0.574  ± 0.21 0.859 
Ovarian 16  0.284  ± 0.173 0.176  ± 0.086 0.620 
Lung 14  0.359  ± 0.317 0.450  ± 0.205 1.253 
Esophageal 10 0.816  ± 0.33 0.861  ± 0.277 1.055 
Pancreas
Normal 4  0.471  ± 0.264 1.911  ± 0.263 4.057 
Pancreas
Tumor 4  0.215  ± 0.119 1.369  ± 1.334 6.367
Table 2. Expression levels of the antigenic vimentin isoform in human tumors. The numbers shown are 
averaged integrated intensity measurements (± SD) for two vimentin spots, with “A” being the ubiquitous spot 
and “B” being the identiﬁ  ed antigenic spot.
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to be related to the total level of vimentin protein 
expression. Further, we were unable to demonstrate 
aberrant N- or O-linked glycosylation of vimentin 
in the pancreatic tumor cell lines (data not 
shown). 
Although the vimentin autoantibodies were 
largely restricted to patients with pancreatic cancer 
among the subject groups we investigated, further 
studies are needed to determine the speciﬁ  city of 
the vimentin antibodies to pancreatic cancer. For 
example, although increased levels of vimentin 
antibodies were found in pancreatic cancer, as 
compared to chronic pancreatitis and healthy indi-
viduals, the relationship between tumor burden, 
tumor staging and antibody levels needs further 
clariﬁ  cation. Assessment of the utility of vimentin 
autoantibodies as diagnostic markers in pancreatic 
cancer also needs to be addressed in further studies. 
It is clear, however, that the proteomic approach 
we have implemented, which allows for the 
screening of natural forms of proteins as expressed 
in tumor cells, has the potential to identify novel 
antigens that may have utility for cancer screening 
and diagnosis.
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preferentially with a speciﬁ  c domain of the protein, 
a peptide with a molecular weight of 30 kDa that 
is close to the amino-terminal of intact vimentin. 
It should be noted, however, that although we have 
identiﬁ  ed 12 peptides from vimentin by MS/MS 
analysis, the most N-terminal of these started at 
residue 78 of the intact protein. Although the 
epitope that reacts with autoantibodies in pancre-
atic cancer patient’s sera remains undeﬁ  ned, it is 
plausible that the antigenic epitope was exposed 
following proteolytic cleavage of the intact protein 
near the N-terminus.
Most antigens recognized by autoantibodies are 
molecules that exist within cells under normal 
conditions. However the structure, processing 
and/or subcellular localization of some molecules, 
change with cell death. These processed forms are 
recognized by the immune system, leading to the 
development of autoimmunity particularly if the 
dead cells fail to be effectively cleared by phago-
cytosis (28). For example, some autoantigens such 
as the nuclear autoantigen La, or ribonucleoprotein 
Ro move to a region near the cell periphery during 
apoptosis (29–30). Thus, it may be proposed that 
the processing and translocation of cellular anti-
gens to a new sub-cellular compartment could have 
a causative role in autoimmunity. Interestingly, it 
has been recently demonstrated that vimentin is 
secreted by macrophages in response to pro-inﬂ  am-
matory signaling pathways (31). In particular, 
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